The subscription window for the GSP Crop Science IPO opened this morning, Monday, March 16, 2026, and will remain open until Wednesday, March 18, 2026. The company has fixed a price band of ₹304 to ₹320 per share. Retail investors can bid for a minimum of 1 lot (46 shares), requiring an investment of ₹14,720 at the upper price cap.
GSP Crop Science specializes in the development and manufacturing of a wide range of insecticides, herbicides, fungicides, and plant growth regulators. The company operates five manufacturing facilities in Gujarat and Jammu & Kashmir, boasting over 102 granted patents and nearly 524 product registrations.
Financial highlights driving investor interest include:
-
Explosive Profitability: Profit After Tax (PAT) grew from ₹17.57 crore in FY23 to ₹81.42 crore in FY25.
-
Strong H1 Performance: In the first half of FY26, the company has already recorded a PAT of ₹81.07 crore, nearly matching its entire previous year's profit in just six months.
-
Debt Management: Out of the ₹240 crore fresh issue, ₹170 crore is earmarked specifically for the repayment or prepayment of outstanding borrowings, which is expected to significantly lower interest costs and boost net margins.
Key IPO Details & Timetable
| Feature | Details |
| Price Band | ₹304 – ₹320 per share |
| Lot Size | 46 Shares (Min. Investment ₹14,720) |
| Total Issue Size | ₹400 Crore |
| Today's Status (March 16) | Open (Day 1 of 3) |
| Grey Market Premium (GMP) | ₹0 (Trading at Par) |
| Allotment Date | March 20, 2026 |
| Listing Date | March 24, 2026 (BSE & NSE) |
Today’s Real News & Investor Insights
-
Anchor Round Success: On Friday, March 13, the company successfully raised ₹120 crore from anchor investors, including names like Craft Emerging Market Fund and Shine Star Build Cap. This provides a solid foundation for the public issue opening today.
-
Market Sentiment (GMP): Despite strong financial growth, the Grey Market Premium (GMP) is currently ₹0. Analysts suggest this "neutral" start is due to broader market volatility and specific sector risks, such as the potential for a weaker 2026 monsoon due to El Niño conditions.
-
Valuation Benchmarking: At the upper price band of ₹320, the IPO is valued at a P/E of roughly 18.3x (based on FY25 earnings). This is considered a slight premium compared to domestic-focused peers, though the massive profit jump in H1 FY26 makes the forward-looking valuation appear much more attractive.
-
Geographic Risk: A key point for investors today is the company's revenue concentration, with 62% of domestic sales coming from five states (Gujarat, Maharashtra, Andhra, Rajasthan, and Karnataka).
-
Brokerage View: Most analysts have given a "Neutral to Long-term Apply" rating. They recommend watching the QIB (Qualified Institutional Buyer) subscription numbers over the next 48 hours to gauge big-money confidence.